New therapy reduces migraine episodes by up to 50%
Who never had that annoying headache that was not going away at all? This problem is very common, in some cases it can be treated as a migraine, a complication that affects 15% of the Brazilian population, according to the Brazilian Headache Society. Therefore, medical follow-up is extremely important so that some care can be taken during crises, avoiding the aggravation of pain.
Treatment for migraine is currently made with prevention drugs that include neuromodulators, beta blockers, antidepressants, antivertiginals . However, the indication will depend on each case.
In order to make treatment more effective for patients, researchers have developed a new therapy to prevent migraine attacks capable of decreasing both number and degree of migraine. For this finding, two studies were conducted, published this Thursday (30) in "The New England Journal of Medicine." Developed as an injection, this is the first treatment specifically produced to prevent the condition.
The studies analyzed two injections: Erenumab and Fremanezumab. The first drug is actually one of the laboratory-made monoclonal antibodies that attack the brain protein responsible for symptoms (CGRP), such as nausea and severe headaches. In tests performed with the drug Erenumab, produced by the Swiss drugmaker Novartis, found that about 50% of the volunteers had the number of migraine attacks reduced by half versus 26% who received a placebo, which explains the natural flow of the condition.
This study involving Erenumab was performed in 955 patients who received a monthly injection of the drug into the thigh or belly or a placebo version for 24 weeks.
Meanwhile, Fremanezumab, another antibody manufactured by American Teva, had the same result in 41 % of the patients analyzed, against 18% without the same treatment. This drug was tested in 1,130 patients, of which 376 received the drug quarterly, 379, monthly, and 375, placebo.
Participants who received the treatment had on average three days less than migraine attacks each month, when compared to the habitual tendency of the episodes. In addition, those who received the injections with the antibody also showed an improvement in physical fitness during the treatment period. "The study clearly shows that blocking this neuronal pathway [CGRP] can reduce the impact of migraine. patients are receiving treatments that are actually for other diseases, but now they can have a therapy specifically developed for migraine. This represents an incredibly important step in the compression and treatment of the disease, "Peter Goadsby, a professor of neurology at King's College London, leader of one of the trials.
Although further studies need to be performed to prove efficacy, further studies will still be needed to assess long-term side effects. "These patients will have a part of their lives back and society will have these people returning to their jobs," he added.
Colorectal cancer is a tumor that grows from the cells lining the large intestine. At first, it is characterized by small benign nodules, called polyps. But over the course of a few years, these small nodes can undergo transformations, becoming malignant. Food Lifestyle factors seem to play an important role in the origin of this tumor.
Hepatology found that the metabolic syndrome significantly increases the risk of developing the initial state of liver cancer, known as hepatocarcinoma (also known as hepatocellular carcinoma). The analysis, conducted by researchers at the National Cancer Institute, United States, and the Goethe-Universität, Germany, used data from SEER-Medicare - a database of cancer patients from the United States.